Key result
In patients receiving DOACs for VTE, weighing ≥120 kg was associated with a similar incidence of recurrent VTE compared to weighing <120 kg (0.8% vs 1.1%; OR 0.66; 95% CI 0.09-5.14; P=0.69).
Why the study?
Limited clinical data justifying DOAC efficacy in patients weighing ≥120 kg raised concern about using them in this population.
Does direct oral anticoagulant therapy have similar efficacy in preventing recurrent VTE in patients weighing ≥120 kg compared to those weighing <120 kg?
Cohort (n=1,196)
Does direct oral anticoagulant therapy have similar efficacy in preventing recurrent VTE in patients weighing ≥120 kg compared to those weighing <120 kg?
Odds Ratio: 0.66 (95% CI 0.09–5.14)
Absolute Event Rate: 0.8% vs 1.1%
p-value: p=0.69
Direct oral anticoagulants appear to have similar efficacy for VTE treatment in patients weighing ≥120 kg compared to those <120 kg, though the study was underpowered due to low event rates.
No takes yet. Share an insight, caveat, or question.
Supports DOAC use in VTE patients ≥120 kg without adjustment; leaves open need for prospective confirmation.
Aloi et al. (2019) conducted a cohort in Venous thromboembolism (VTE) (n=1,196). Weight ≥120 kg (while on DOACs) vs. Weight <120 kg (while on DOACs) was evaluated on Incidence of recurrent VTEs while on anticoagulation (OR 0.66, 95% CI 0.09-5.14, p=0.69). In patients receiving DOACs for VTE, weighing ≥120 kg was associated with a similar incidence of recurrent VTE compared to weighing <120 kg (0.8% vs 1.1%; OR 0.66; 95% CI 0.09-5.14; P=0.69).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: